Image

Developing a Shared Decision Making Tool for Patients With Surgically Removed Non-small Cell Lung Cancer

Developing a Shared Decision Making Tool for Patients With Surgically Removed Non-small Cell Lung Cancer

Not Recruiting
18 years and older
All
Phase N/A

Powered by AI

Overview

This study observes conversations between non-small cell lung cancer patients and their doctors to support the development of a decision aid that can be used to inform discussions about treatment options for after surgery. Patients who have undergone surgery for their non-small cell lung cancer may have the option of completing additional treatment. Patients contemplating this additional treatment have been shown to be most satisfied with their choice if they perceive an effort by their doctor to share decision making. Shared decision making tools can help doctors guide conversations, offer tailored recommendations, and support deliberation on whether or not to pursue treatment. This study develops a shared decision making tool for patients with surgically removed non-small cell lung cancer contemplating additional treatment.

Description

PRIMARY OBJECTIVE:

I. To develop, in close collaboration with stakeholders, an evidence-based decision aid to inform discussions regarding options for adjuvant treatment in patients with resected non-small cell lung cancer (NSCL) (NSCL adjuvant choice).

OUTLINE

Patient and clinician discussions are observed to support refinement of a decision aid. Clinicians may use a prototype of the decision aid in discussions with their patients and may complete a questionnaire.

Eligibility

Inclusion Criteria:

  • PATIENTS:
  • Adults >= 18 years with biopsy proven resected non-small cell lung cancer (NSCLC)
  • Appointments to discuss adjuvant treatment of resected NSCLC
  • CLINICIANS:
  • Clinicians who meet with patients to discuss adjuvant treatment of resected NSCLC
  • PAG MEMBERS:
  • Adults >= 18 years
  • Member of the Knowledge and Evaluation Research (KER) Unit Patient Advisory Group (PAG)

Exclusion Criteria:

  • PATIENTS
  • Major barriers to providing informed consent (i.e., dementia, severe hearing or visual impairment)

Study details
    Lung Non-Small Cell Carcinoma

NCT05416983

Mayo Clinic

28 November 2025

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.